By Fineline Cube 
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) has secured approvals from Singapore’s Health Sciences Authority (HSA) and Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) for its self – developed anti – PD – 1 monoclonal antibody Hansizhuang (serplulimab), marketed as Hetronifly in Europe, for the treatment of extensive – stage small cell lung cancer (ES – SCLC). The drug will be available under the brand name Zerpidio in these markets.
Global Presence and Patient Impact
Serplulimab has already gained approval in over 30 countries and regions around the world, benefiting more than 110,000 patients. Its expanded reach underscores Fosun Pharma’s commitment to addressing unmet medical needs in oncology.
Strategic Licensing and Commercialization Partnerships
Henlius entered into an exclusive licensing agreement with KGbio in 2019, granting the latter development and commercialization rights for the drug in ASEAN countries. In August 2023, the partnership was expanded to grant KGbio exclusive rights for two indications, including ES – SCLC, in 12 Middle East and North Africa (MENA) countries. KGbio will spearhead commercialization efforts in Southeast Asian markets going forward, marking a significant step in the drug’s global expansion.-Fineline Info & Tech